Abstract
Much interest has focused on the newer incretin-based therapeutic modalities for diabetes, especially GLP-1 analogues. While the comparatively older GLP-1 analogs, exenatide and liraglutide, have been discussed extensively in literature, much less is known about the newer GLP-1 analogues in the pipeline. This review focuses on the newer molecules being studied, the newer routes of administration being tried, some recent patents and potential uses for these multifaceted compounds.
Keywords: GLP-1 analogs, long acting exenatide, albiglutide, taspoglutide, GLP-2 analogs, GLP-1 secretagogues
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Title: GLP - 1 Analogs: Newer Molecules, Newer Uses
Volume: 3 Issue: 2
Author(s): Sanjay Kalra, Bharti Kalra and Amit Kumar
Affiliation:
Keywords: GLP-1 analogs, long acting exenatide, albiglutide, taspoglutide, GLP-2 analogs, GLP-1 secretagogues
Abstract: Much interest has focused on the newer incretin-based therapeutic modalities for diabetes, especially GLP-1 analogues. While the comparatively older GLP-1 analogs, exenatide and liraglutide, have been discussed extensively in literature, much less is known about the newer GLP-1 analogues in the pipeline. This review focuses on the newer molecules being studied, the newer routes of administration being tried, some recent patents and potential uses for these multifaceted compounds.
Export Options
About this article
Cite this article as:
Kalra Sanjay, Kalra Bharti and Kumar Amit, GLP - 1 Analogs: Newer Molecules, Newer Uses, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2009; 3 (2) . https://dx.doi.org/10.2174/187221409788452309
DOI https://dx.doi.org/10.2174/187221409788452309 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications
Coronaviruses Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Reactive Oxygen Species in Vascular Wall
Cardiovascular & Hematological Disorders-Drug Targets Written Consent to Use the Drug in Children: The Problem of Off-Label Drugs
Current Pharmaceutical Design Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders
Current Medicinal Chemistry Big Data and Genome Editing Technology: A New Paradigm of Cardiovascular Genomics
Current Cardiology Reviews Decreasing Systemic Toxicity Via Transdermal Delivery of Anticancer Drugs
Current Drug Metabolism Cellular Cardiomyoplasty – Challenges of a New Era
Current Tissue Engineering (Discontinued) Therapeutic Strategies of Plant-derived Compounds for Diabetes Via Regulation of Monocyte Chemoattractant Protein-1
Current Medicinal Chemistry Long-term Success and Follow-up After Atrial Fibrillation Ablation
Current Cardiology Reviews Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Current Drug Therapy Strategies for Enhancing Progenitor Cell Mobilization and Function in Diabetes
Current Vascular Pharmacology Editorial (Thematic Issue: Mechanistic Biomarkers: The Field for the Development of Non-Pharmaceutical and Pharmaceutical Approaches to Diagnostics, Prevention and Treatment of Chronic Diseases)
Current Pharmaceutical Design Green Tea Attenuates Cardiovascular Remodeling and Metabolic Symptoms in High Carbohydrate-Fed Rats
Current Pharmaceutical Biotechnology Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions
Current Cardiology Reviews Antidotal Effects of Curcumin Against Agents-Induced Cardiovascular Toxicity
Cardiovascular & Hematological Disorders-Drug Targets Metabolic Therapy of Heart Failure
Current Pharmaceutical Design Sirtuins: Novel Players in Male Reproductive Health
Current Medicinal Chemistry